Enterprise Value
-24.13M
Cash
92.75M
Avg Qtr Burn
-19.71M
Short % of Float
1.87%
Insider Ownership
19.59%
Institutional Own.
41.53%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
HB-200 (TheraT® LCMV) + pembrolizumab Details Cancer, Human papillomavirus, Head and neck squamous cell carcinoma | Phase 2/3 Initiation | |
HB-400 Details Hepatitis B | Phase 2 Initiation | |
HB-202/HB-201 Details Cancer, Human papillomavirus | Phase 1/2 Data readout | |
HB-500 Details Human immunodeficiency virus | Phase 1b Data readout | |
HB-700 Details Cancer, Lung cancer, Colorectal cancer , Pancreatic cancer | Phase 1 Initiation | |
HB-101 (VaxWave®) Details Cytomegalovirus, Infectious disease, Kidney transplantation | Failed Discontinued | |
HB-300 Details Cancer, Castration-resistant prostate cancer | Failed Discontinued |